• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cancers, Vol. 15, Pages 3992: Long-Term Adverse Effects of Neck Radiotherapy in Childhood on the Carotid Arteries in Survivors of Hodgkin Lymphoma
Conclusions: Vascular changes in survivors of childhood Hodgkin lymphoma after neck RT seem to be long-term. Therefore, these patients may have an increased risk of stroke. We suggest refinement of international guidelines according to our results.
Source: Cancers - August 6, 2023 Category: Cancer & Oncology Authors: Matja ž Popit Marjan Zaletel Bojana Žvan Lorna Zadravec Zaletel Tags: Article Source Type: research

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
ConclusionFor patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Source: Clinical and Translational Oncology - April 23, 2023 Category: Cancer & Oncology Source Type: research

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
CONCLUSIONS: In this study, we observed a higher VTE risk, but not ATE risk, in patients with ALK-rearranged NSCLC relative to those without ALK rearrangement. Prospective studies are warranted to evaluate thromboprophylaxis in ALK-positive NSCLC.PMID:37014824 | DOI:10.1093/oncolo/oyad061
Source: The Oncologist - April 4, 2023 Category: Cancer & Oncology Authors: Oded Icht Avi Leader Erez Batat Lilach Yosef Tzippy Shochat Daniel A Goldstein Elizabeth Dudnik Galia Spectre Pia Raanani Ariel Hammerman Alona Zer Source Type: research

Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
ConclusionFor patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.
Source: Clinical and Translational Oncology - December 31, 2022 Category: Cancer & Oncology Source Type: research

Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke
CONCLUSION: This study highlights that elevated baseline AF/stroke-related risk does not adversely impact TTD and TTNT outcomes associated with ibrutinib use. Additionally, TTNT was significantly longer for patients treated with ibrutinib vs. other regimens.PMID:35973891 | DOI:10.1016/j.clml.2022.07.004
Source: Clinical Lymphoma and Myeloma - August 16, 2022 Category: Cancer & Oncology Authors: Anna Narezkina Nausheen Akhter Xiaoxiao Lu Bruno Emond Sumeet Panjabi Shaun P Forbes Annalise Hilts Stephanie Liu Marie-H élène Lafeuille Patrick Lefebvre Qing Huang Michael Choi Source Type: research

Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials
CONCLUSION: In contemporary chest RT-based clinical trials, reported CVD rates were lower than expected population rates.PMID:35198835 | PMC:PMC8844682 | DOI:10.1016/j.adro.2021.100888
Source: Cancer Control - February 24, 2022 Category: Cancer & Oncology Authors: Rahul N Prasad Mark McIntyre Avirup Guha Rebecca R Carter Vedat O Yildiz Electra Paskett Maryam Lustberg Patrick Ruz Terence M Williams Onaopepo Kola-Kehinde Eric D Miller Daniel Addison Source Type: research

Informing Radiotherapy Decisions in Stage I/IIa Hodgkin Lymphoma: Modelling Life Expectancy Using Radiation Dosimetry
Blood Adv. 2021 Dec 6:bloodadvances.2021006254. doi: 10.1182/bloodadvances.2021006254. Online ahead of print.ABSTRACTIn recent randomized trials, omitting consolidative radiotherapy in early-stage Hodgkin lymphoma (ESHL) increased relapses. However, decades of follow-up are required to observe whether lower initial disease control is compensated by reduced risk of late effects. Extrapolation beyond trial follow-up is therefore necessary to inform current treatment decisions. To this end, we developed a microsimulation model to estimate lifetime quality-adjusted life years (QALYs) after combined modality treatment (CMT) or ...
Source: Cancer Control - December 6, 2021 Category: Cancer & Oncology Authors: David Andrew Jones Paolo Candio Rebecca Shakir Georgios Ntentas Johanna Ramroth Alastair M Gray David John Cutter Source Type: research

Pages: 1  2  3  4